Elevance Health, Inc.
ELV
$529.93
$2.970.56%
| Weiss Ratings | ELV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Good | |||
| Risk Index | Good | |||
| Risk Grade | B | |||
| Reward Grade | B | |||
| Rating Factors | ELV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | Weak | |||
| Growth Index | Fair | |||
| Efficiency Index | Excellent | |||
| Solvency Index | Excellent | |||
| Total Return Index | Fair | |||
| Volatility Index | Good | |||
| Beta / Standard Deviation | ELV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.49 | |||
| Price History | ELV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 3.19% | |||
| 30-Day Total Return | 2.86% | |||
| 60-Day Total Return | 6.46% | |||
| 90-Day Total Return | 12.15% | |||
| Year to Date Total Return | 9.71% | |||
| 1-Year Total Return | 16.30% | |||
| 2-Year Total Return | 4.66% | |||
| 3-Year Total Return | 40.52% | |||
| 5-Year Total Return | 103.23% | |||
| 52-Week High % Change | -0.44% | |||
| 52-Week Low % Change | 30.99% | |||
| Price | ELV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $539.11 | |||
| 52-Week Low Price | $412.00 | |||
| 52-Week Low Price (Date) | Jul 12, 2023 | |||
| 52-Week High Price (Date) | Apr 18, 2024 | |||
| Valuation | ELV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 123.51B | |||
| Enterprise Value | 143.84B | |||
| Price/Earnings (TTM) | 20.08 | |||
| Earnings Per Share (TTM) | 26.46 | |||
| Earnings Per Share Growth | 4.85% | |||
| Price/Earnings To Growth | 4.21 | |||
| Price/Sales (TTM) | 0.72 | |||
| Price/Book (Q) | 3.04 | |||
| Enterprise Value/Revenue (TTM) | 0.85 | |||
| Price | $525.19 | |||
| Enterprise Value/EBITDA (TTM) | 11.60 | |||
| Enterprise Value/EBIT | 13.31 | |||
| Market Cap Category | Large Cap | |||
| Dividends and Shares | ELV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 234.20M | |||
| Dividend Yield | 1.14% | |||
| Div. Per Share (Most Recent) | $1.63 | |||
| Dividend Per Share (TTM) | $6.07 | |||
| Payout Ratio (TTM) | 22.79% | |||
| Dividend Per Share (Most Recent) | $1.63 | |||
| Company Info | ELV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 833 401 1577 | |||
| Address | 220 Virginia Avenue Indianapolis, IN 46204 | |||
| Website | www.elevancehealth.com | |||
| Country | United States | |||
| Year Founded | 2001 | |||
| Profitability | ELV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 6.37% | |||
| Profit Margin | 3.63% | |||
| Management Effectiveness | ELV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 6.20% | |||
| Return on Equity | 15.95% | |||
| Income Statement | ELV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 144.59B | |||
| Total Revenue (TTM) | 171.75B | |||
| Revenue Per Share | $733.33 | |||
| Gross Profit (TTM) | 47.66B | |||
| EBITDA (TTM) | 12.57B | |||
| EBIT (TTM) | 10.95B | |||
| Net Income (TTM) | 6.24B | |||
| Net Income Avl. to Common (TTM) | 6.24B | |||
| Total Revenue Growth (Q YOY) | 0.96% | |||
| Earnings Growth (Q YOY) | 12.23% | |||
| EPS Diluted (TTM) | 26.46 | |||
| EPS Diluted Growth (Q YOY) | 15.54% | |||
| Balance Sheet | ELV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 36.27B | |||
| Cash Per Share (Q) | $154.85 | |||
| Total Current Assets (Q) | 60.95B | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 40.71B | |||
| Current Ratio (Q) | 1.375 | |||
| Book Value Per Share (Q) | $174.62 | |||
| Total Assets (Q) | 111.89B | |||
| Total Current Liabilities (Q) | 44.33B | |||
| Total Debt (Q) | 26.45B | |||
| Total Liabilities (Q) | 71.18B | |||
| Total Common Equity (Q) | 40.61B | |||
| Cash Flow | ELV - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -4.70B | |||
| Cash from Financing (TTM) | -2.79B | |||
| Net Change in Cash (TTM) | -3.92B | |||
| Levered Free Cash Flow (TTM) | 39.13M | |||
| Cash from Operations (TTM) | 3.57B | |||
